Status:
RECRUITING
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
Lead Sponsor:
Zhejiang University
Collaborating Sponsors:
The Second Hospital of Hebei Medical University
Second Affiliated Hospital of Nanchang University
Conditions:
Intraductal Papillary Mucinous Neoplasm
Eligibility:
All Genders
Up to 90 years
Brief Summary
This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.
Detailed Description
This prospective study was designed to explore biomarkers for detecting early carcinogenesis of IPMN. This study intends to prospectively and continuously enroll IPMN patients, and regularly collect b...
Eligibility Criteria
Inclusion
- clinically diagnosed as IPMN;
- without other malignant tumor;
- agree to sign informed consent.
Exclusion
- with mental disorders which can affect cognition and cooperation;
- with serious blood diseases or taking drugs that can affect peripheral blood
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2033
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT05433935
Start Date
July 1 2022
End Date
December 31 2033
Last Update
January 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310009